US 11,554,103 B2Granted

Compositions and methods to reduce pharmaceutical-induced toxicity

AssigneeNorthwestern University

InventorsDalton James Surmeier, Jr., Steven M. Graves

Life of this patent

Estimating the term…

Abstract

Provided herein are compositions and methods to reduce toxicity resulting from pharmaceutical treatment, that can lead to increased risk of developing Parkinson's disease (PD) and/or acceleration of PD-associated deterioration.

Claims9

Dependent claims

A method comprising co-administering (i) a monoamine oxidase (MAO) inhibitor and (ii) amphetamine and/or methamphetamine to a subject suffering from attention deficit hyperactive disorder (ADHD), narcolepsy, or obesity.

Dependencies are inferred from the claim text.

Facts

Application: 15/809,079Filed 10 Nov 2017 · us provisional application
Priority: 10 Nov 2016
Published: US 2018/0153839 A17 Jun 2018
Granted: 17 Jan 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/395
Heterocyclic compounds: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61P 25/16
For treating abnormal movements, e.g. chorea, dyskinesia: anti-Parkinson drugs
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Family

Application62/420,369Us provisional application · filed 10 Nov 2016
US 2018/0153839 A1Pre-grant publication · published 7 Jun 2018
US 11,554,103 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results